Managing the Demands of Patient Recruitment
A globally renowned patient recruitment company faced a significant increase in materials requiring translation to support multiple studies.
RWS can translate information on the production, distribution, and use of medical or in-vitro devices.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
RWS provides translation, content management, and intellectual property capabilities for the medical device and in-vitro diagnostic (IVD) industries. We connect our clients with companies worldwide by communicating content at scale to help protect and realise ideas and innovations.
Our teams offer localisation, translation and transcreation services, as well as translation management technology, machine translation, and translation productivity tools, to help companies expand their global reach.
RWS’ solutions can improve the efficiency of translation processes and reduce their costs, as well as shorten times to market. By making use of our capabilities, you can create real value for your teams and ecosystem partners to improve translation outcomes for scientists, medical representatives and professionals, in addition to patients.
RWS can confidently handle all requests for translations through our understanding of and emphasis on the medical device and IVD industries.
We begin by thoroughly analysing projects to decide the most appropriate translation solution for each request and can adapt our methods to meet clients’ needs as necessary. We follow flexible procedures that allow us to deliver the most timely and cost-effective results.
The translation of information related to the production, distribution, and use of medical and IVD devices is essential for companies that serve global populations—and it presents several challenges. Translating information for medical and IVD companies requires not only linguistic skills but a deep understanding of the industry and highly specialised regulatory knowledge.
For more than 30 years, RWS Life Sciences has been a trusted partner to medical and IVD companies, offering ISO-certified multilingual solutions and translation services in more than 330 language variants. Our decades of dedicated partnerships have led to a deep understanding of the industries in which our clients operate.
RWS’ global team of account managers, project managers, tested linguists, reviewers, terminologists, linguistic engineers, solution architects, and subject matter experts have deep translation, localisation, and regulatory experience.
We can deliver your translated multilingual content quickly, correctly, and in compliance with the Medical Device Regulation 2017/745 (MDR) and In Vitro Diagnostics regulation 2017/746 (IVDR) in all target markets.
We understand that our clients need to work with a partner that has extensive industry experience, can deliver a team of highly specialised translators who are both linguistic and subject matter experts, and can provide insights and validation regarding the regulations that govern the development and trade of medical devices worldwide.
In addition, RWS knows that high-quality, compliant content is critical for your work at every stage of the value chain, from research and development (R&D) to production to patient engagement. To complement our linguistic work, we offer a full suite of consulting, engineering, and business intelligence services.
A globally renowned patient recruitment company faced a significant increase in materials requiring translation to support multiple studies.
Do you want your trial participants to sift through complex and jargon-filled clinical trial summaries? Do you believe that every patient, healthcare professional, and caregiver deserves easy access to vital medical information?
One of the world’s largest pharmaceutical companies saves over ten million in translation spend through partnership and innovation with RWS Life Sciences.
Global content explosion needs deeper collaboration between humans and machines. AI is revolutionising how you can create, manage, translate and understand content.
When faced with unprecedented time constraints and high volume, innovative ideas and core partnerships are key. This is especially true for the Regulatory and Clinical portfolios, which require local language translation of more than 40,000 documents a year to enable successful authorisation.
Timeliness and quality of translations are key across a leading pharmaceutical corporation, however within the regulatory team of submissions management, it is an imperative requirement.
A life sciences company providing a full-line of clinical laboratory and end-to-end drug development services had a need to leverage RWS’ translation services.
Evolve, built by humans for humans, is a pioneering innovation that will enable life science companies to benefit from a platform that achieves human-like translation quality, almost instantly, significantly reducing the time required for manual processing during the translation process.
A leading global pharmaceutical company asked RWS to deliver a machine translation (MT) solution that would deliver efficiency, scalability and return-on-investment for a patient safety/pharmacovigilance (PV) programme. After careful analysis of the current PV programme, we identified several redundancies and non-cohesive work strategies.
Like many other large global pharmaceutical companies, this industry leader was faced with the challenge of decentralised translation spend and countless suppliers operating under different guidelines. This common scenario made it difficult to control global spend, leverage important translation assets, reduce cost, innovate and drive the necessary standardisation to ensure quality.
RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, announces that its near-term science-based emissions reduction target has been approved by the Science-Based Targets initiative (SBTi). The approval is a key milestone in RWS’ sustainability journey.
RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, has joined forces with industry leaders to bridge the gap between rapid advances in AI innovation and policymaking through Meta’s Open Loop programme.
RWS, a unique, world-leading provider of technology-enabled language, content and intellectual property solutions, announces that its linguistic AI solution, Evolve, has been awarded the ‘Machine Translation Innovation Award’ at the 2024 AI Breakthrough Awards.
RWS, a company providing translation services for the pharmaceutical and life science industries, is among those exhibiting at DIA Europe 2024, the largest life sciences conference in Europe.
RWS, a company providing translation services for pharmaceutical and life sciences companies, is exhibiting at the CAHP conference in Palm Desert, California, this month. To be held from 23-25 October, the event will be the 37th edition of the annual conference.
Life sciences-focused translation company RWS will be giving two presentations at this year’s International Society for Quality-of-Life Research (ISOQOL) conference. The trade show will take place in Calgary, Alberta, from 18-21 October.
RWS, a leading provider of translation services for pharmaceutical and life sciences companies, will be exhibiting at the RAPS Convergence trade fair in Montreal from 3-5 October.
Pharmaceutical and life sciences translation company RWS will be giving a talk at the DIA 2023 conference, which will take place from 25-29 June in Boston, Massachusetts.
Pharmaceutical-focused translation company RWS will be exhibiting at the ISPOR conference taking place in Boston, Massachusetts, from 7-10 May.
As the world’s first genuine intelligence linguistic AI solution, RWS’ Evolve allows pharmaceutical companies to harness the latest innovations in Generative AI in a fully secure, end-to-end Linguistic AI solution in a cost-efficient manner.